• Bishwajit Bhattacharya, Reza Askari, Kimberly A Davis, Jon Dorfman, Ahmed I Eid, Ahmed E Elsharkawy, George Kasotakis, Sandra Mackey, Stephen Odom, Barbara U Okafor, Michael Rosenblatt, Alexander Ruditsky, George Velmahos, and Adrian A Maung.
• Yale School of Medicine, New Haven, CT, United States. Electronic address: Bishwajit.bhattacharya@yale.edu.
• Injury. 2020 Sep 1; 51 (9): 1994-1998.

BackgroundLiver and spleen injuries are the most commonly injured solid organs, the effects of anticoagulation on these injuries has not yet been well characterized.Study DesignMulticenter retrospective study.ResultDuring the 4-year study period, 1254 patients, 64 (5%) on anticoagulation (AC), were admitted with liver and/or splenic injury. 58% of patients had a splenic injury, 53% had a liver injury and 11% had both. Patients on AC were older than non-AC patients (mean age 60.9 vs. 38.6 years, p < 0.001). The most common AC drug was warfarin (70%) with atrial fibrillation (47%) the most common indication for AC. There was no significant difference in AAST injury grade between AC and non-AC patients (median grade 2), but AC patients required a blood product transfusion more commonly (58 vs 40%, p = 0.007) particularly FFP (4 vs 19%, p < 0.01). Among those transfused, non-AC patients required slightly more PRBC (5.7 vs 3.8 units, p = 0.018) but similar amount of FFP (3.2 vs 3.1 units, p = 0.92). The two groups had no significant difference in the rates of initial non-operative management (50% (AC) vs 56% (non-AC), p = 0.3)) or failure of non-operative management (7 vs 4%, p = 0.16). AC patients were more likely to be managed initially with angiography (36 vs 20%, p = 0.001) while non-AC patients with surgery (24% vs 13%, p = 0.04). There was no significant difference in LOS and mortality.ConclusionThe use of anticoagulation did not result in a difference in outcomes among patients with spleen and/or liver injuries.Published by Elsevier Ltd.

16 keywords...

hide…